Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes

Abstract

survival. Actuarial 1-year local control was 86%; for the groups treated in 3, 5, 8 and 12 fractions, it was 90%, 83%, 85% and 71%, respectively. There were no significant differences between the groups. Actuarial survival at 1 year was 81%. Grade 3 toxicity was found in 2.9% of the patients, 9 patients having grade 3 (abdominal pain, nausea, fatigue, bile duct stenosis, and hematoma); 2 patients having grade 4 (gallbladder and gastric perforation); and one having grade 5 (hepatobiliary disorder). Conclusion: This large multi-institutional study of 560 liver metastases treated with SBRT confirms the high rates of local control and limited toxicity in a large patient cohort. In clinical practice, SBRT should thus be seen as a valuable part of the multidisciplinary approach to treating liver metastases.

Liquid Biopsies for Molecular Biology-Based Radiotherapy

“…However, 79% of patients had undetectable ctDNA midway through chemoradiotherapy despite only 13% of patients experiencing a pathologic complete response, suggesting that more sensitive analysis approaches may be necessary to identify patients with persistent local disease. We recently reported that ctDNA concentration a median of 3 weeks into chemoradiotherapy for lung cancer was significantly associated with risk of disease progression and overall survival [ 137 ]. Furthermore, integrating ctDNA analysis with complementary outcome predictors may improve risk stratification [ 138 ].…”